Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

MBX Biosciences Inc

MBX ✓ COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Mid Cap Analyst: BUY

Last Close

$68.62

▲ +3.36%

Market Cap $3.30B · Vol 88.29K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.30B

Mid Cap

Div Yield

N/A

EPS Growth

-30.48%

YoY

RSI (14)

54.15

Momentum

Beta

N/A

vs Market

52W High

$72.64

5.53% below

52W Low

$9.63

612.56% above

Volume

88.29K

Avg 154.78K

P/B

3.84

Price-to-book

ROE

-27.76%

Return on equity

Free Float

76.98%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, MBX Biosciences Inc (MBX) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does MBX pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+3.16%

+10.68%

+115.45%

+92.54%

YTD

+117.56%

+394.02%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-86,971,000.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	-27.76%
ROA · ROIC	-26.61% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	3.84
P/FCF	N/A
EPS Growth	-30.48%
Outstanding Shares	48.16M

Technical Indicators

50-Day SMA	$59.99
200-Day SMA	$39.20
RSI (14)	54.15
Beta	N/A
52-Week High	$72.64
52-Week Low	$9.63

Volume Today	88.29K
Avg Daily Volume (30D)	154.78K
Relative Volume	0.57x
Volatility (10D)	31.70
Volatility (30D)	60.97
Free Float	76.98%

Analyst Consensus

BUY

Current Price $68.62

Mean Target $88.40

52W Low$9.63 52W High$72.64

Current

Target

$9.63 $72.64

Current Analyst target

+28.83% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG00W7W53N4

ISINUS55287L1017

CountryUnited States of America

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateNov 4, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG +1.02% ONC BeOne Medicines AG +1.18% RVMD Revolution Medicines Inc -0.09% 068270.KS Celltrion Inc -2.27% ABVX Abivax SA +1.53%

Company Profile

MBX Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. It has built its proprietary Precision Endocrine Peptide platform to develop precision peptide therapies that are designed to overcome key limitations of current peptide therapies. Its product candidates and programs include MBX 2109, MBX 1416 and Obesity portfolio. MBX 2109 is a parathyroid hormone peptide prodrug that is designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. MBX 1416 is designed to be a long-acting glucagon-like peptide-1 (GLP-1), receptor antagonist, as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. MBX 4291 is designed to be a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide, receptor co-agonist prodrug.